2026-03-19 10:05:05
SAB Biotherapeutics Announces $85 Million Public Offering of Common Stock and Pre-Funded Warrants
Expected Stock impact: Noticeably Positive
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company, has announced the commencement of an underwritten public offering of its common stock and pre-funded warrants. The offering includes 19,324,677 shares of common stock priced at $3.85 per share, along with pre-funded warrants to purchase up to 2,753,246 shares at a price of $3.8499 per warrant. The company has granted underwriters a 30-day option to purchase an additional 3,311,688 shares. The gross proceeds from the offering are expected to be approximately $85 million, before deducting underwriting discounts and commissions. The net proceeds will primarily fund the continued development of SAB-142, a treatment for type 1 diabetes, and for general corporate purposes. The offering is expected to close on or about March 19, 2026, subject to customary closing conditions. This move is seen as a strategic effort to bolster the company's financial position and support its clinical trials, which could enhance its market presence and investor confidence.
